Kerri Anne Stellato
About Kerri Anne Stellato
Chief Commercial Officer at Watchmaker Genomics
Kerri Stellato currently holds the position of Chief Commercial Officer at Watchmaker Genomics. She initially joined the company in February 2021 as Vice President of Strategic Marketing and Sales Operations. Overseeing the commercial strategy, she is instrumental in driving the company's growth within the genomics sector. Her role includes managing sales operations, developing marketing strategies, and spearheading initiatives to enhance market penetration.
Over 20 Years of Industry Experience in Genomics
Kerri Stellato brings over two decades of experience in the genomics industry to her role at Watchmaker Genomics. Over the years, she has demonstrated expertise in developing commercial organizations from the ground up, particularly within early-stage start-up genomics companies. Her extensive background enables her to effectively drive commercial strategies and achieve significant market growth.
Former Leadership Roles at Kapa Biosystems and Roche Diagnostics
Kerri Stellato joined Kapa Biosystems in 2012, where she played a crucial role in managing the expansion of the sales team and introducing new NGS products to the market. Following Kapa Biosystems' acquisition by Roche Diagnostics in 2015, she managed the US Life Sciences Sales organization for Roche, further honing her skills in sales management and commercial strategy.
Vice President of Sales and Marketing at seqWell
Prior to her current role, Kerri Stellato served as Vice President of Sales and Marketing for seqWell. In this position, she was responsible for overseeing the marketing strategies and sales operations, contributing to the company's growth and expansion within the genomics sector. Her efforts helped to establish seqWell as a competitive player in the market.
Education and Expertise in Cell and Molecular Biology
Kerri Stellato earned her Bachelor of Arts in Cell and Molecular Biology from the University of Chicago. This academic background laid the foundation for her extensive career in the genomics industry. Her expertise in cell and molecular biology supports her deep understanding of the scientific principles underlying genomic technologies, which she leverages to inform commercial strategies.